Imagine what you could do if working with poorly soluble compounds was not an insurmountable issue. 

Our SILSOL^® silica active ingredient delivery technology combines Grace's extensive expertise in mesoporous silica gel, novel application methods, and patent pending technologies to accelerate the screening and development of solubility enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.

Grace's SILSOL® silica active ingredient delivery technology offers five major benefits:

• Enhanced bioavailability through delivery of the amorphous form of active ingredients
• Sustained stability from amorphous solid dispersions that prevent crystallization/re-crystallization
• Pharmacopoeia acceptance of our cGMP manufactured silica that conforms to global monographs
• Scalable cGMP excipient manufacturing from grams to tons quantities
• FDA compliant materials listed on the FDA inactive ingredient database (IID)

Compared to other bioavailability enhancing techniques such as particle size reduction, complexation, lipid-based systems, and polymer-based solid dispersions, our SILSOL^® silica technology introduces techniques that are easier to screen and work in combination with existing technologies to improve usage and stability, thereby reducing the time needed to scale up.